Skip Navigation


Annals of Oncology Advance Access originally published online on October 9, 2006
Annals of Oncology 2007 18(1):45-51; doi:10.1093/annonc/mdl334
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/1/45    most recent
mdl334v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kennecke, H.
Right arrow Articles by Gelmon, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennecke, H.
Right arrow Articles by Gelmon, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

breast cancer

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen

HF Kennecke1,2,3,*, IA Olivotto2,3,4,5, C Speers3,4, B Norris2,3,6, SK Chia1,2,3, C Bryce1,2,3 and KA Gelmon1,2,3

1 Division of Medical Oncology, British Columbia (BC) Cancer Agency
2 Department of Medicine, University of British Columbia, Vancouver, BC
3 Breast Cancer Outcomes Unit
4 Population and Preventive Oncology Programs
5 Victoria
6 Fraser Valley, BC Cancer Agency, Canada

* Correspondence to: Dr H. Kennecke, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6. Tel: +1 604 877 6000, ext 2707; E-mail: hkenneck{at}bccancer.bc.ca

Background: Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer. An individualized estimate of the risk of relapse and death after 5 years of tamoxifen could improve decisions regarding extended hormonal therapy.

Methods: The British Columbia Breast Cancer Outcomes database was used to identify women aged 45 years or older at the time of diagnosis with early-stage (I–IIIA) breast cancer who received tamoxifen and were disease free 5 years after diagnosis. Ten-year breast cancer event rates and mortality were calculated as well as annualized hazard rates of recurrence.

Results: A total of 1086 women were identified with a median age of 64 years and follow-up of 10.5 years. The relative risk (RR) of death was 3.1 (P = 0.003) and for recurrence was 1.7 (P = 0.037) for N1 (one to three positive nodes) versus N0 (zero nodes positive) disease. N2 (four to nine nodes positive) had a RR of 5.8 (P < 0.001) for death and 3.0 (P = 0.002) for recurrence. Low tumor grade and high ER level subgroups had a more favorable prognosis. Annual breast cancer risk between years 6 and 10 was, respectively, 2.2%, 3.5% and 7.6% for N0, N1 and N2 disease and 2.6% and 4.5% for T1 and T2 breast cancer.

Conclusion: T and N stages predicted late relapse and death from breast cancer in a population-based cohort of postmenopausal women. Risk estimates reported herein may be used to optimize decision making regarding adjuvant therapy after 5 years of tamoxifen.

Key words: breast cancer, estrogen receptor, mortality, relapse, risk, tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 1. [Extract] [Full Text]  





Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.